Back to Agenda
Not Can, but Should: How do we WANT AI/ML to Transform Clinical Development?
Session Chair(s)
Morgan Hanger, MPA
Executive Director
Clinical Trials Transformation Initiative (CTTI), United States
Visionary leaders will debate three options for the ideal AI-transformed future state of the clinical trials enterprise. Attendees will appraise these big ideas, consider market implications, and reflect on their roles in getting us there.
Learning Objective : Evaluate three “big goals" for AI transformation of clinical development (eg, 10xing drugs reaching the market, eliminating human trial participants); Discuss the infrastructure implications of each goal (eg., with more drug candidates advancing, how will the system need to adapt?); Identify necessary, accompanying regulatory changes (eg, how will we meet increased demand for reviews?)
Speaker(s)
Panelist
Tala Fakhouri, PHD, MPH
Parexel International, United States
Vice President, AI & Digital Policy, Real-World Research
Panelist
Henry Wei
Regeneron Pharmaceuticals, United States
Head of Development Innovation
Panelist
Gabriel Westman, MD, PHD, MSC
Swedish Medical Products Agency, Sweden
Head of Artificial Intelligence
Have an account?